Möchten Sie immer auf dem neuesten Stand bleiben?

Results presented by the LiBBY study team at the Alzheimer’s Association International Conference (“AAIC”) demonstrated statistically significant improvements in agitation symptoms compared with...

Study at International Alzheimer's Conference Finds Brain Training Reduces Amyloid

Vaccinex reports new biomarker research and plans for Phase 2 randomized clinical trial of pepinemab in Alzheimer's Disease at the AAIC in July

AC Immune to Showcase Neurodegenerative Disease Pipeline with Three Presentations at AAIC® 2026 Lausanne, Switzerland, July 7, 2026 -- AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical...

Therini Bio announced the dosing of the first patient in their Phase 1b trial evaluating THN391 in Alzheimer's Disease

TORONTO, July 28, 2025 (GLOBE NEWSWIRE) --  Results from a large study announced today provides those with elevated Alzheimer’s risk a new path for changing the trajectory of their brain health. The...

Therini Bio's novel approach to treating neurodegenerative diseases yielded positive results in a Phase 1a study evaluating its lead candidate, THN391.

AC Immune Unveils Novel Therapeutic Antibody Drug Conjugate (ADC) Technology for Improved Efficacy in Neurodegenerative Diseases at AAIC 2024 morADC combines proprietary brain-penetrant small...

Fosgonimeton mitigated amyloid-β-induced toxicity, lowered pTau levels and reduced disruption of protein clearance mechanisms that may contribute to pTau pathology Fosgonimeton treatment,...

Longeveron Phase 2a clinical results in Alzheimer's Disease selected for Featured Research oral presentation at Alzheimer’s Association International Conf